Abstract
In spite of recent advances in chemotherapy, the treatment of pulmonary aspergilloma remains unsatisfactory. To evaluate the clinical efficacy and safety of combination therapy for pulmonary aspergilloma, we conducted a multi-institutional prospective study using micafungin (MCFG) and itraconazole (ITCZ). Adult patients who fulfilled the criteria for pulmonary aspergilloma were enrolled in this study. After patient consent had been obtained, intravenous MCFG 150 mg/day and an oral capsule of ITCZ 200 mg/day were administered for at least 1 month. The primary endpoint was the response assessed using an algorithm that incorporated the levels of improvement by evaluating clinical symptoms and signs, mycological and serological tests, and diagnostic imaging. A total of 17 patients were enrolled from three facilities. The response rate to the combination therapy was 58.8% (10/17). The long-term control in the group of patients who responded to treatment was better than that in the group of patients who did not respond. Adverse events occurred in 6 of the 17 patients (35.3%), but there were no severe adverse events. MCFG-ITCZ combination therapy appeared to be relatively safe and effective in patients with pulmonary aspergilloma.
References
Jul 31, 2001·FEMS Immunology and Medical Microbiology·C P SemighiniG H Goldman
Jul 23, 2003·Cancer·Dimitrios P KontoyiannisIssam I Raad
Feb 26, 2004·Antimicrobial Agents and Chemotherapy·Melissa D JohnsonJohn H Rex
Jun 3, 2004·Lancet·Annemarie E BrouwerThomas S Harrison
Aug 4, 2004·Scandinavian Journal of Infectious Diseases·Shigeru KohnoHideo Ikemoto
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kieren A MarrLawrence Corey
Oct 16, 2004·Expert Review of Anti-infective Therapy·Yasuhito Higashiyama, Shigeru Kohno
Jul 16, 2005·Current Opinion in Microbiology·Fredj Tekaia, Jean-Paul Latgé
Feb 16, 2006·Transplantation·Nina SinghShahid Husain
Apr 25, 2006·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·Masaki OkamotoKazuhiro Hatta
May 9, 2006·The Journal of Infection·David W DenningThomas F Patterson
Jun 29, 2006·Current Opinion in Infectious Diseases·Karl V Clemons, David A Stevens
Jan 24, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Arlo UptonKieren A Marr
May 17, 2007·Current Medicinal Chemistry·Fumiaki IkedaYoshiyasu Aoki
Jun 15, 2007·Bone Marrow Transplantation·M D Johnson, J R Perfect
Aug 28, 2007·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hiroshi OuchiYoichi Nakanishi
Jul 22, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brahm H SegalBen E De Pauw
Nov 6, 2008·Transplant Infectious Disease : an Official Journal of the Transplantation Society·D P KontoyiannisK A Marr
Citations
Feb 18, 2016·Respiratory Investigation·Koichi Izumikawa
Nov 3, 2012·Chest·Jared N KravitzMarc A Judson
Mar 19, 2013·Mycoses·Ritesh AgarwalArunaloke Chakrabarti
Feb 1, 2014·The Journal of Infection·D A EnochJ A Karas
Feb 26, 2016·Chest·Cendrine GodetUNKNOWN ACHROSCAN Study Group
Jul 27, 2017·The Journal of Pharmacy and Pharmacology·Akash Patil, Soumyajit Majumdar
Nov 11, 2017·The Journal of Antimicrobial Chemotherapy·Cendrine GodetUNKNOWN CPAnet
Jul 2, 2014·Antimicrobial Agents and Chemotherapy·Yali LiRuoyu Li
Sep 30, 2018·Mycoses·Akaninyene A OtuChris Kosmidis
Apr 7, 2020·Expert Review of Respiratory Medicine·Inderpaul Singh SehgalRitesh Agarwal
Jun 17, 2020·Mycoses·Felix BongominDavid W Denning
Oct 24, 2019·BMJ : British Medical Journal·Daniel A Culver, Marc A Judson